Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Quality of Life After AVR
Author(s): Meng He , Jinwei Zhang , Jianbo Yu , et al Added: 1 month ago

Heart Failure
RDW Prognostic Marker in HF and Predictor for Iron Replacement Responsivene
Author(s): Artemio García-Escobar , Rosa Lázaro-García , Javier Goicolea-Ruigómez , et al Added: 6 months ago

Heart Failure
TAVR is Ready for Most Low-risk Patients
Author(s): Ahmad Jabri , Anas Alameh , Gennaro Giustino , et al Added: 9 months ago

Intervention

Vascular Disease and Surgery
TCT 24: The TAVR UNLOAD Trial
Author(s): Nicolas M Van Mieghem Added: 7 months ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) in addition to optimal heart failure therapy (OHFT) compared to OHFT alone in patients with heart failure and moderate aortic stenosis.Dr Nicolas M Van Mieghem (Erasmus University Medical Center, Rotterdam, NL) joins us onsite at TCT Conference to discuss the findings from TAVR UNLOAD (NCT02661451)… View more

Heart Failure

Intervention
EuroPCR 25: The TRINITY Trial
Author(s): Thomas Modine Added: 3 weeks ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement… View more

Heart Failure

Intervention
ACC 25: The MyPEAK-1 Study
Author(s): Milind Y Desai Added: 2 months ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene… View more

Heart Failure
Mayra Guerrero
Dr Mayra Guerrero is a board-certified Interventional Cardiologist with special interest in structural heart interventions, particularly non-surgical heart valve repair and replacement. Her clinical expertise includes percutaneous coronary artery revascularization and percutaneous treatment of structural heart disease. Her main research interest is the development of transcatheter mitral valve… View more
Dr Gilbert Tang is Surgical Director of the Structural Heart Program at the Mount Sinai Health System and Professor of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai in New York. He has performed over 2000 cases of transcatheter aortic valve replacement (TAVR), transcatheter mitral valve repair (MitraClip), transcatheter mitral valve replacement, and tricuspid valve repair… View more
Thomas Modine
Research Area(s) / Expertise:

Stroke

 Job title: Cardiovascular and Thoracic Surgeon
Prof Thomas Modine is professor of cardiovascular surgery at Bordeaux University Hospital, Bordeaux, FR. He is a renowned surgeon in transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), minimally invasive surgery and valve sparing techniques. He is also leading basic science research programmes and is developing a percutaneous mitral programme with IP. He… View more
New York Valves 2025
Start date: Jun 25, 2025 End date: Jun 27, 2025
New York Valves 2025 summit, sponsored by the Cardiovascular Research Foundation, is set to take place from June 25th to 27th at Jacob K. Javits Convention Center in New York. The program will offer insights into the latest practises in valvular and structural heart care. View more

Heart Failure

Intervention